Mutation Spectrum and Novel Rare Variants in a Han Chinese Hearing Loss Cohort Using a Tiered Sequencing Strategy
Molecular Genetics & Genomic Medicine · 2026
DOI: 10.1002/mgg3.70291 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Genetics & Genomic Medicine, 2026. Verfasst von Yu Zhang und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Laboratory Medicine, Chongqing Center for Clinical Laboratory, Chongqing Academy of Medical Sciences, Chongqing General Hospital, Chong…. Hauptthemen laut MEDLINE: Hearing Loss, Mutation. Die Arbeit nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: General Program of National Natural Science Foundation of China, Chongqing special project for technological innovation and application development, The Joint project of Chongqing Health Commission and Science and Technology Bureau.
Abstract (Originalsprache)
Background
Hereditary hearing loss is a genetically heterogeneous disorder posing challenges for molecular diagnosis. This study aimed to characterize the mutation spectrum, including rare and previously unreported variants, using a tiered strategy in a Han Chinese cohort from Southwest China.
Methods
In this retrospective study, 43 patients underwent targeted hotspot screening, followed by whole‐exome sequencing in 11 patients with no hotspot variants detected. Variants were annotated and interpreted according to American College of Medical Genetics and Genomics guidelines.
Results
Initial hotspot screening established molecular diagnoses in 23 patients based on seven pathogenic or likely pathogenic variants in MT ‐ RNR1 , GJB2 , and SLC26A4 . Whole‐exome sequencing identified six additional rare variants in CDH23 , ILDR1 , OTOF , and SLC12A2 , and established two diagnoses involving ILDR1 and CDH23 . A previously unreported SLC12A2 missense variant, c. 2936A >G (p. Glu979Gly ) was identified as a variant of uncertain significance and retained as a candidate finding. CDH23 c. 5311C >T (p.Arg1771Ter) has not previously been reported in Han Chinese patients with hearing loss, to our knowledge.
Conclusions
These findings expand the mutation spectrum of hereditary hearing loss in a Han Chinese cohort from Southwest China and highlight the practical value of a tiered testing strategy integrating targeted hotspot screening with whole‐exome sequencing.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Laboratory Medicine, Chongqing Center for Clinical Laboratory, Chongqing Academy of Medical Sciences, Chongqing General Hospital, Chongqing University, Chongqing, China.
- Department of Medical Laboratory, Dianjiang General Hospital of Chongqing, Chongqing, China.
ORCID-Profile: Yu Zhang
Förderung
- General Program of National Natural Science Foundation of China
- Chongqing special project for technological innovation and application development
- The Joint project of Chongqing Health Commission and Science and Technology Bureau
Zitieren
APA
Zhang, Y., Yuan, S., Wan, Y., Li, T., Xu, L., Yang, W., & Niu, C. (2026). Mutation Spectrum and Novel Rare Variants in a Han Chinese Hearing Loss Cohort Using a Tiered Sequencing Strategy. Molecular Genetics & Genomic Medicine. https://doi.org/10.1002/mgg3.70291
Vancouver
Zhang Y, Yuan S, Wan Y, Li T, Xu L, Yang W, et al. Mutation Spectrum and Novel Rare Variants in a Han Chinese Hearing Loss Cohort Using a Tiered Sequencing Strategy. Molecular Genetics & Genomic Medicine. 2026. doi:10.1002/mgg3.70291
BibTeX
@article{Zhang2026,
author = {Zhang, Yu and Yuan, Shimei and Wan, Yafang and Li, Tian and Xu, Lanlan and Yang, Wei and Niu, Changchun},
title = {Mutation Spectrum and Novel Rare Variants in a Han Chinese Hearing Loss Cohort Using a Tiered Sequencing Strategy},
journal = {Molecular Genetics & Genomic Medicine},
year = {2026},
doi = {10.1002/mgg3.70291}
}
EUVIMED